Company Name, Ticker, Industry, else..

Biocorrx Inc (BICX)

Sector • Healthcare Industry • Healthcare Facilities

Industry • Healthcare Facilities

Sector • Healthcare

Biocorrx Inc 's

Name: Biocorrx Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

BICX Sales vs. its Competitors Q2 2026

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Biocorrx Inc , faster than the decline experienced by the competitors recorded a net loss, as well as most of its competitors.

<< BICX Stock Performance Comparisons

<< See the full list of BICX competitors

*Market share is calculated based on total revenue.

BICX's Stock Performance relative to its Competitors

Publicly Traded Peers of Biocorrx Inc

Compass Pathways Plc
Share Performance

+13.34%

This Quarter

Compass Pathways Plc

Profile

Compass Pathways Plc is a mental healthcare company focused on developing innovative therapies for treatment-resistant depression. They are pioneering the use of psychedelic-assisted therapy to address this significant unmet medical need. With a business model centered around clinical research and drug development, their goal is to bring their therapies to market and improve the lives of patients suffering from depression.

More about Compass Pathways Plc's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 1,759.903 mill.	$ - mill.	$ -178.796 mill.

Cybin Inc
Share Performance

-18.02%

One Year

Cybin Inc

Profile

Helus Pharma develops therapeutics for mental health and neurological conditions.

More about Cybin Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 167.442 mill.	$ 159.148 mill.	$ -86.663 mill.

Definium Therapeutics Inc
Share Performance

+191.20%

This Year

Definium Therapeutics Inc

Profile

Definium Therapeutics develops pharmaceutically optimized psychedelic drug candidates.

More about Definium Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 4,321.176 mill.	$ - mill.	$ -237.543 mill.

Two Hands Corporation
Share Performance

0.00%

This Year

Two Hands Corporation

Profile

Two Hands Corporation is a business that operates as an online marketplace connecting buyers and sellers of various products and services. The company charges fees to sellers for listing their products and facilitates the transaction process between buyers and sellers. By providing a platform for individuals and businesses to trade, Two Hands Corporation generates revenue through commissions on sales and advertising fees.

More about Two Hands Corporation's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ - mill.	$ - mill.	$ -2.069 mill.

Sources: Biocorrx Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Sunday, August 30, 2026 10:19 AM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Biocorrx Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.